Jian M, Chang W, Ren L, et al. - Researchers examined patients with synchronous colorectal liver-limited metastases (CLLMs) undergoing conversion therapy for the role of hepatic steatosis (HS). CT scan was performed on 406 patients with initially unresectable CLLMs who accepted conversion therapy in multidisciplinary team, to assess the presence of hepatic steatosis. Patients were divided into two groups: the HS group (n = 124) and the non-HS group (n = 282). Pretreatment HS was identified as an independent predictor for conversion hepatectomy rate, and as an independent prognostic factor for progression-free survival (HR, 0.493) and overall survival (HR, 0.559) among CLLM patients who underwent conversion therapy.